The power of PRALUENT

LDL-C reductions with 75 mg and 150 mg1

View PRALUENT efficacy

 

Who is PRALUENT for?

Patients you often see in clinical practice

View PRALUENT patient types

 

Dosing flexibility

2 doses with 2 levels of efficacy1

Learn more about PRALUENT dosing

 

Savings and long-term support

Comprehensive assistance with cost, coverage, and more

Get started today with MyPRALUENT®

 

New insurance may mean new requirements. Learn how to prepare your office and patients

Dosing Information

  • The recommended starting dose of PRALUENT is 75 mg administered subcutaneously once every 2 weeks, since the majority of patients achieve sufficient LDL-C reduction with this dosage. If the LDL-C response is inadequate, the dosage may be increased to the maximum dosage of 150 mg administered every 2 weeks

*Formulary data are provided by Managed Markets Insights & Technology, LLC (MMIT) and are current as of April 1, 2016. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage.2

Reference:

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2015.